Long-term survival data of patients with limited disease small cell lung cancer: a retrospective analysis

被引：8

作者：

Doshita, Kosei ^{[1
,2
]}

Kenmotsu, Hirotsugu ^{[1
]}

Omori, Shota ^{[1
]}

Tabuchi, Yuya ^{[3
]}

Kawabata, Takanori ^{[4
]}

Kodama, Hiroaki ^{[1
]}

Nishioka, Naoya ^{[1
]}

Miyawaki, Eriko ^{[1
]}

Iida, Yuko ^{[1
]}

Miyawaki, Taichi ^{[1
]}

Mamesaya, Nobuaki ^{[1
]}

Kobayashi, Haruki ^{[1
]}

Ko, Ryo ^{[1
]}

Wakuda, Kazushige ^{[1
]}

Ono, Akira ^{[1
]}

Naito, Tateaki ^{[1
]}

Murakami, Haruyasu ^{[1
]}

Mori, Keita ^{[4
]}

Harada, Hideyuki ^{[3
]}

Kaneko, Takeshi ^{[2
]}

Takahashi, Toshiaki ^{[1
]}

机构：

[1] Shizuoka Canc Ctr, Div Thorac Oncol, Shimonagakubo, Shizuoka 10074118777, Japan

[2] Yokohama City Univ, Grad Sch Med, Dept Pulmonol, Kanazawa Ku, 3-9 Fukuura, Yokohama, Kanagawa 2360004, Japan

[3] Shizuoka Canc Ctr, Radiat & Proton Therapy Ctr, 1007 Shimonagakubo,Nagaizumi Cho, Shizuoka 4118777, Japan

[4] Shizuoka Canc Ctr, Clin Res Ctr, Shimonagakubo, Shizuoka 10074118777, Japan

来源：

INVESTIGATIONAL NEW DRUGS | 2022年 / 40卷 / 02期

关键词：

Chemoradiotherapy; Prognosis; Progression-free survival; Small cell lung cancer; Survival rate; THORACIC RADIOTHERAPY; PROGNOSTIC-FACTOR; CHEST RADIOTHERAPY; TUMOR VOLUME; STAGE; CONCURRENT; METAANALYSIS; CISPLATIN; ETOPOSIDE; CHEMORADIOTHERAPY;

D O I：

10.1007/s10637-021-01183-6

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Introduction: In patients with limited disease small cell lung cancer (LD-SCLC) treated with concurrent chemoradiotherapy (CCRT), long-term survival data have not been fully evaluated. Moreover, the association between long-term prognosis and prognostic factors has not been sufficiently investigated. Methods: In this retrospective study, we evaluated the efficacy of CCRT in 120 patients with LD-SCLC with a plan for curative CRT using concurrent accelerated hyperfractionated radiotherapy. Results: The patients had a median age of 65.5 years, predominantly male (73%), and had clinical stage III disease (80%). The median follow-up time for overall survival (OS) was 72.2 months, median OS was 42.5 months, and the 3-year and 5-year survival rates were 52.4% and 41.8%, respectively. The median progression-free survival (PFS) was 12.5 months, and the 3-year and 5-year PFS rates were 37.6% and 33.6%, respectively. The 5-year OS rates of patients who achieved PFS at each time point were 70.9%, 83.6%, and 91.9% at 12, 24, and 36 months, respectively. The gradual increase in the 5-year OS rate following PFS extension and initial depression of the Kaplan-Meier curve showed disease progression frequently occurred in the first 2 years after initiation of CCRT. The Cox proportional hazards model showed no significant factors correlated with long-term survival through univariate and multivariate analyses. Although the prognostic factors associated with long-term prognosis in LD-SCLC were not identified, the 5-year survival rate was 41.8%, and among patients without disease progression at 2 years, the 5-year survival rate was 83.6%. Conclusion: These data suggested that the prognosis of patients with LD-SCLC was improving.

引用

页码：411 / 419

页数：9

共 32 条

[1] Progression-free survival at 2 years is a reliable surrogate marker for the 5-year survival rate in patients with locally advanced non-small cell lung cancer treated with chemoradiotherapy [J].